Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8
datasets available to search
ShareScore release 0.7.1
Dataset results
8 results for “Health Authorities”
Comparative analysis of health authorities spokesperson and health influencer during the COVID-19 pandemic: A case in Indonesia
<p><span><strong>Background</strong>: </span><span>Concerns over an infodemic following a surge in health misinformation circulating on social media sets out the government's priority for Indonesia. Given the urgent work on the coronavirus disease 2019 (COVID-19) response, the government collaborated with health-related spokespersons and influencers with a medical background by starting a COVID-19 public education campaign on social media. A collaborative initiative involved health spokespersons from government and non-government to clarify misinformation about COVID-19.</span></p> <p><span><strong>Methods</strong>: </span><span>The primary purpose of this research is to compare government and non-government spokespersons by examining their role in educating about the COVID-19 vaccine and health services. This study employed comparative factor analysis and non-participatory observation toward the media activity of spokespersons in Indonesia. Using a questionnaire, this study examines the dimensions of public campaigns, risk communication, health and emergency, leadership, and communication from Indonesian spokespersons. The data collection was conducted in two stages. The first stage was a pilot study that collected data from 102 respondents, the second stage collected data from 276 respondents.</span></p> <p><span><strong>Results</strong>: </span><span>Findings show that utilizing the spokesperson is important due to its capabilities of reaching diverse audiences, and improving public engagement, trustworthiness, and credibility.</span></p> <p><span><strong>Conclusions</strong>: </span><span>With the combination of health authorities spokespersons and health influencers in Indonesia, this study provides valuable insights for communication management in developing and supporting the role of health authorities from the government, non-government as well as medical sectors.</span></p>
Comparative analysis of health authorities spokesperson and health influencer during the COVID-19 pandemic: A case in Indonesia
Open the record for dataset details and reuse information.
Data from: Quality of evidence considered by Health Canada in granting full market authorization to new drugs with a conditional approval: a retrospective cohort study
Objectives: This study examines the characteristics of studies that Health Canada uses to grant full marketing authorization for products given a conditional approval between January 1, 1998 and June 30, 2017. Design: Cohort study. Data sources: Journal articles listing drugs that fulfilled their conditions and received full marketing authorization, Notice of Compliance database, Notice of Compliance with conditions web site, Qualifying Notices listing required confirmatory studies, clinicaltrials.gov, PubMed, Embase, companies making products being analyzed, journal articles resulting from confirmatory studies. Interventions: None Primary and secondary outcome measures: Characteristics of studies - study design (randomized controlled trials, observational), primary outcome used (clinical, surrogate), blinding, number of patients in studies, patient median age, number of men and women. Results: Eleven companies confirmed 36 publications for 19 products (21 indications). Twenty-nine out of the 36 studies were randomized controlled trials (RCTs) but only 10 stated if they were blinded. Twenty used surrogate outcomes. The median age of patients was 56 (interquartile range (IQR) 44, 61). The median number of men per study/trial was 184 (IQR 58, 514) versus women - 141 (IQR 46, 263). Conclusions: Postmarket studies required by Health Canada had more rigorous methodology than those required by either the Food and Drug Administration or the European Medicines Agency. There were still deficiencies in these studies. The absence of blinding in the majority of RCTs may introduce bias in their results. The use of surrogate outcomes especially in oncology trials means that improvements in survival are not available. The relatively young age of patients, even for products for cancer, means that predicting how the elderly will respond is often unknown. The almost universal finding that men outnumbered number women may make it hard to differentiate responses by sex. These results raise potential concerns about the quality of evidence that Health Canada accepts.
Data from: Quality of evidence considered by Health Canada in granting full market authorization to new drugs with a conditional approval: a retrospective cohort study
Open the record for dataset details and reuse information.
Figure 1 from: Toshev A, Petkova-Gueorguieva E, Mihaylova A, Pavlova G, Parahuleva N, Balkanski S, Peikova L, Getova V, Madzharov V, Gueorguiev S (2024) Health Emergency Preparedness and Response Authority's (HERA) role in dealing with the monkeypox emergency in the European Union. Pharmacia 71: 1-6. https://doi.org/10.3897/pharmacia.71.e117944
Figure 1 Distribution of cases by month (January 2022-August 2022) for the six WHO regions.
Figure 2 from: Toshev A, Petkova-Gueorguieva E, Mihaylova A, Pavlova G, Parahuleva N, Balkanski S, Peikova L, Getova V, Madzharov V, Gueorguiev S (2024) Health Emergency Preparedness and Response Authority's (HERA) role in dealing with the monkeypox emergency in the European Union. Pharmacia 71: 1-6. https://doi.org/10.3897/pharmacia.71.e117944
Figure 2 Distribution of cases by month (January 2022-August 2023) for the six WHO regions.
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
ClinicalTrials.gov study NCT02902822. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Durham Housing Authority (DHA) Community Health Advisor (CHA) Smoking Cessation Project
ClinicalTrials.gov study NCT04114526. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.